{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T23:50:10Z","timestamp":1795132210165,"version":"4.10.3"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Key Research and Development Program of China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>BRCAness is a homologous recombination repair (HRR) deficiency phenotype mimicking <jats:italic>BRCA1\/2<\/jats:italic> loss, leading to PARP inhibitor sensitivity in BRCA-associated cancers including pancreatic cancer<jats:sup>1\u20137<\/jats:sup>. However, how to induce BRCAness in BRCA-proficient tumors remains unclear. We identify OFD1 as a positive regulator of BRCA1 in human pancreatic cancer cells and specimens, with its overexpression correlating with poor prognosis. OFD1 depletion impairs HRR and confers synthetic lethality with PARP inhibitors. Mechanistically, OFD1 interacts with E2F4 in the cytosol to prevent assembly of the transcriptional repressor DREAM complex at the <jats:italic>BRCA1<\/jats:italic> promoter. Targeting OFD1 or disrupting its interaction with E2F4 promotes E2F4 nuclear translocation and DREAM complex formation, suppressing <jats:italic>BRCA1<\/jats:italic> expression. OFD1 inhibition synergizes with olaparib in pancreatic cancer xenograft, spontaneous, and patient-derived xenograft models, and in other BRCA-associated cancer models. These findings reveal a mechanism of <jats:italic>BRCA1<\/jats:italic> transcriptional regulation and highlight OFD1 as a therapeutic target to induce BRCAness in BRCA-proficient pancreatic cancer.<\/jats:p>","DOI":"10.1038\/s41467-025-62295-8","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T16:44:50Z","timestamp":1754412290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["OFD1 inhibition induces BRCAness to create a therapeutic vulnerability to PARP inhibition in pancreatic cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Peng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2658-1937","authenticated-orcid":false,"given":"Junjie","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7527-0828","authenticated-orcid":false,"given":"Xiaoxiao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8070-5275","authenticated-orcid":false,"given":"Lingxi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3994-248X","authenticated-orcid":false,"given":"Baiyong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9843-8788","authenticated-orcid":false,"given":"Zaiming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6979-955X","authenticated-orcid":false,"given":"Qing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"62295_CR1","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-019-1382-1","volume":"571","author":"P Jonsson","year":"2019","unstructured":"Jonsson, P. et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature 571, 576\u2013579 (2019).","journal-title":"Nature"},{"key":"62295_CR2","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord, C. J. & Ashworth, A. PARP inhibitors: Synthetic lethality in the clinic. Science 355, 1152\u20131158 (2017).","journal-title":"Science"},{"key":"62295_CR3","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"Robson","year":"2017","unstructured":"Robson et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 1700\u20131700 (2017).","journal-title":"N. Engl. J. Med."},{"key":"62295_CR4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(17)32418-2","volume":"390","author":"DS Dizon","year":"2017","unstructured":"Dizon, D. S. PARP inhibitors for targeted treatment in ovarian cancer. Lancet 390, 1929\u20131930 (2017).","journal-title":"Lancet"},{"key":"62295_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123\u2013134 (2009).","journal-title":"N. Engl. J. Med."},{"key":"62295_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan, T. et al. Maintenance olaparib for germline BRCA-mutated metastatic Pancreatic Cancer. N. Engl. J. Med. 381, 317\u2013327 (2019).","journal-title":"N. Engl. J. Med."},{"key":"62295_CR7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/gutjnl-2019-319984","volume":"70","author":"L Perkhofer","year":"2021","unstructured":"Perkhofer, L. et al. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut 70, 606\u2013617 (2021).","journal-title":"Gut"},{"key":"62295_CR8","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M. & Maitra, A. Pancreatic cancer: Advances and challenges. Cell 186, 1729\u20131754 (2023).","journal-title":"Cell"},{"key":"62295_CR9","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff, J. et al. Pancreatic cancer. Nat. Rev. Dis. Prim. 2, 16022 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"62295_CR10","first-page":"111","volume":"58","author":"MH Katz","year":"2008","unstructured":"Katz, M. H., Hwang, R., Fleming, J. B. & Evans, D. B. Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J. Clin. 58, 111\u2013125 (2008).","journal-title":"CA Cancer J. Clin."},{"key":"62295_CR11","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801\u20131806 (2008).","journal-title":"Science"},{"key":"62295_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495\u2013501 (2015).","journal-title":"Nature"},{"key":"62295_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc1431","volume":"4","author":"SA Narod","year":"2004","unstructured":"Narod, S. A. & Foulkes, W. D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 4, 665\u2013676 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"62295_CR14","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"62295_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev-biochem-013118-111058","volume":"88","author":"WX Zhao","year":"2019","unstructured":"Zhao, W. X., Wiese, C., Kwon, Y., Hromas, R. & Sung, P. The BRCA tumor suppressor network in chromosome damage repair by homologous recombination. Annu. Rev. Biochem. 88, 221\u2013245 (2019).","journal-title":"Annu. Rev. Biochem."},{"key":"62295_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","volume":"23","author":"FJ Groelly","year":"2023","unstructured":"Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N. & Tarsounas, M. Targeting DNA damage response pathways in cancer. Nat. Rev. Cancer 23, 78\u201394 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"62295_CR17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917 (2005).","journal-title":"Nature"},{"key":"62295_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin, N. J. & Szabo, C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat. Rev. Drug Discov. 19, 711\u2013736 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"62295_CR19","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1053\/j.gastro.2021.01.220","volume":"160","author":"T Golan","year":"2021","unstructured":"Golan, T. et al. Genomic features and classification of homologous recombination deficient Pancreatic ductal adenocarcinoma. Gastroenterology 160, 2119\u20132132.e2119 (2021).","journal-title":"Gastroenterology"},{"key":"62295_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110\u2013120 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"62295_CR21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm.2377","volume":"17","author":"N Johnson","year":"2011","unstructured":"Johnson, N. et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat. Med. 17, 875\u2013882 (2011).","journal-title":"Nat. Med."},{"key":"62295_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","volume":"36","author":"V Quereda","year":"2019","unstructured":"Quereda, V. et al. Therapeutic targeting of CDK12\/CDK13 in triple-negative breast cancer. Cancer Cell 36, 545\u2013558.e547 (2019).","journal-title":"Cancer Cell"},{"key":"62295_CR23","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s43018-022-00438-2","volume":"3","author":"YY Chu","year":"2022","unstructured":"Chu, Y. Y. et al. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat. Cancer 3, 1211\u20131227 (2022).","journal-title":"Nat. Cancer"},{"key":"62295_CR24","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ccell.2020.10.009","volume":"38","author":"J Han","year":"2020","unstructured":"Han, J. et al. Elevated CXorf67 expression in PFA ependymomas suppresses DNA repair and sensitizes to PARP inhibitors. Cancer Cell 38, 844\u2013856 (2020).","journal-title":"Cancer Cell"},{"key":"62295_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ccell.2019.07.007","volume":"36","author":"S Parvin","year":"2019","unstructured":"Parvin, S. et al. LMO2 Confers synthetic lethality to PARP inhibition in DLBCL. Cancer Cell 36, 237\u2013249 (2019).","journal-title":"Cancer Cell"},{"key":"62295_CR26","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.devcel.2009.12.022","volume":"18","author":"V Singla","year":"2010","unstructured":"Singla, V., Romaguera-Ros, M., Garcia-Verdugo, J. M. & Reiter, J. F. Ofd1, a human disease gene, regulates the length and distal structure of centrioles. Dev. Cell 18, 410\u2013424 (2010).","journal-title":"Dev. Cell"},{"key":"62295_CR27","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1242\/jcs.077156","volume":"124","author":"CA Lopes","year":"2011","unstructured":"Lopes, C. A. et al. Centriolar satellites are assembly points for proteins implicated in human ciliopathies, including oral-facial-digital syndrome 1. J. Cell Sci. 124, 600\u2013612 (2011).","journal-title":"J. Cell Sci."},{"key":"62295_CR28","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/hmg\/6.7.1163","volume":"6","author":"SA Feather","year":"1997","unstructured":"Feather, S. A., Woolf, A. S., Donnai, D., Malcolm, S. & Winter, R. M. The oral-facial-digital syndrome type 1 (OFD1), a cause of polycystic kidney disease and associated malformations, maps to Xp22.2-Xp22.3. Hum. Mol. Genet. 6, 1163\u20131167 (1997).","journal-title":"Hum. Mol. Genet."},{"key":"62295_CR29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nature12606","volume":"502","author":"Z Tang","year":"2013","unstructured":"Tang, Z. et al. Autophagy promotes primary ciliogenesis by removing OFD1 from centriolar satellites. Nature 502, 254\u2013257 (2013).","journal-title":"Nature"},{"key":"62295_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37340-z","volume":"14","author":"M Cao","year":"2023","unstructured":"Cao, M. et al. An actin filament branching surveillance system regulates cell cycle progression, cytokinesis and primary ciliogenesis. Nat. Commun. 14, 1687 (2023).","journal-title":"Nat. Commun."},{"key":"62295_CR31","first-page":"2016","volume":"55","author":"L Badea","year":"2008","unstructured":"Badea, L., Herlea, V., Dima, S. O., Dumitrascu, T. & Popescu, I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepato Gastroenterol. 55, 2016\u20132027 (2008).","journal-title":"Hepato Gastroenterol."},{"key":"62295_CR32","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1038\/s41588-024-01914-4","volume":"56","author":"AM Khaliq","year":"2024","unstructured":"Khaliq, A. M. et al. Spatial transcriptomic analysis of primary and metastatic pancreatic cancers highlights tumor microenvironmental heterogeneity. Nat. Genet. 56, 2455\u20132465 (2024).","journal-title":"Nat. Genet."},{"key":"62295_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-014-0105-3","volume":"6","author":"S Haider","year":"2014","unstructured":"Haider, S. et al. A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Genome Med. 6, 105 (2014).","journal-title":"Genome Med."},{"key":"62295_CR34","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168\u20131178 (2015).","journal-title":"Nat. Genet."},{"key":"62295_CR35","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1158\/0008-5472.CAN-15-2841","volume":"76","author":"S Yang","year":"2016","unstructured":"Yang, S. et al. A Novel MIF signaling pathway drives the malignant character of pancreatic cancer by targeting NR3C2. Cancer Res. 76, 3838\u20133850 (2016).","journal-title":"Cancer Res."},{"key":"62295_CR36","doi-asserted-by":"publisher","first-page":"53165","DOI":"10.18632\/oncotarget.10242","volume":"7","author":"J Jiang","year":"2016","unstructured":"Jiang, J. et al. Globally increased ultraconserved noncoding RNA expression in pancreatic adenocarcinoma. Oncotarget 7, 53165\u201353177 (2016).","journal-title":"Oncotarget"},{"key":"62295_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03354-z","volume":"7","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. Splice variants as novel targets in pancreatic ductal adenocarcinoma. Sci. Rep. 7, 2980 (2017).","journal-title":"Sci. Rep."},{"key":"62295_CR38","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S1097-2765(00)80202-6","volume":"4","author":"ME Moynahan","year":"1999","unstructured":"Moynahan, M. E., Chiu, J. W., Koller, B. H. & Jasin, M. Brca1 controls homology-directed DNA repair. Mol. Cell 4, 511\u2013518 (1999).","journal-title":"Mol. Cell"},{"key":"62295_CR39","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1126\/science.285.5428.747","volume":"285","author":"Q Zhong","year":"1999","unstructured":"Zhong, Q. et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 285, 747\u2013750 (1999).","journal-title":"Science"},{"key":"62295_CR40","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.1648","volume":"8","author":"MT Certo","year":"2011","unstructured":"Certo, M. T. et al. Tracking genome engineering outcome at individual DNA breakpoints. Nat. Methods 8, 671\u2013676 (2011).","journal-title":"Nat. Methods"},{"key":"62295_CR41","doi-asserted-by":"crossref","unstructured":"Chen, B. R. et al. LIN37-DREAM prevents DNA end resection and homologous recombination at DNA double-strand breaks in quiescent cells. Elife 10, e68466 (2021).","DOI":"10.7554\/eLife.68466"},{"key":"62295_CR42","doi-asserted-by":"publisher","first-page":"12085","DOI":"10.1093\/nar\/gkaa965","volume":"48","author":"S Allmann","year":"2020","unstructured":"Allmann, S. et al. Benzo[a]pyrene represses DNA repair through altered E2F1\/E2F4 function marking an early event in DNA damage-induced cellular senescence. Nucleic Acids Res. 48, 12085\u201312101 (2020).","journal-title":"Nucleic Acids Res."},{"key":"62295_CR43","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/nar\/gkv927","volume":"44","author":"M Fischer","year":"2016","unstructured":"Fischer, M., Quaas, M., Steiner, L. & Engeland, K. The p53-p21-DREAM-CDE\/CHR pathway regulates G\/M cell cycle genes. Nucleic Acids Res. 44, 164\u2013174 (2016).","journal-title":"Nucleic Acids Res."},{"key":"62295_CR44","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1101\/gad.2034211","volume":"25","author":"L Litovchick","year":"2011","unstructured":"Litovchick, L., Florens, L. A., Swanson, S. K., Washburn, M. P. & DeCaprio, J. A. DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev. 25, 801\u2013813 (2011).","journal-title":"Genes Dev."},{"key":"62295_CR45","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.molcel.2021.02.001","volume":"81","author":"MJ Kim","year":"2021","unstructured":"Kim, M. J. et al. PAF remodels the DREAM complex to bypass cell quiescence and promote lung tumorigenesis. Mol. Cell 81, 1698\u20131714 (2021).","journal-title":"Mol. Cell"},{"key":"62295_CR46","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1038\/s41388-019-0767-9","volume":"38","author":"AE Schade","year":"2019","unstructured":"Schade, A. E., Oser, M. G., Nicholson, H. E. & DeCaprio, J. A. Cyclin D-CDK4 relieves cooperative repression of proliferation and cell cycle gene expression by DREAM and RB. Oncogene 38, 4962\u20134976 (2019).","journal-title":"Oncogene"},{"key":"62295_CR47","doi-asserted-by":"crossref","unstructured":"Kaplan, A. R. et al. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1\/2 and RAD51. Sci. Transl. Med. 11, eaav4508 (2019).","DOI":"10.1126\/scitranslmed.aav4508"},{"key":"62295_CR48","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1158\/0008-5472.CAN-12-3270","volume":"73","author":"VA Yakovlev","year":"2013","unstructured":"Yakovlev, V. A. Nitric oxide-dependent downregulation of BRCA1 expression promotes genetic instability. Cancer Res. 73, 706\u2013715 (2013).","journal-title":"Cancer Res."},{"key":"62295_CR49","doi-asserted-by":"publisher","first-page":"34471","DOI":"10.1074\/jbc.M205827200","volume":"277","author":"MD Apostolova","year":"2002","unstructured":"Apostolova, M. D., Ivanova, I. A., Dagnino, C., D\u2019Souza, S. J. A. & Dagnino, L. Active nuclear import and export pathways regulate E2F-5 subcellular localization. J. Biol. Chem. 277, 34471\u201334479 (2002).","journal-title":"J. Biol. Chem."},{"key":"62295_CR50","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1073\/pnas.94.10.5095","volume":"94","author":"GJ Lindeman","year":"1997","unstructured":"Lindeman, G. J., Gaubatz, S., Livingston, D. M. & Ginsberg, D. The subcellular localization of E2F-4 is cell-cycle dependent. Proc. Natl. Acad. Sci. USA 94, 5095\u20135100 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62295_CR51","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1242\/jcs.109.7.1717","volume":"109","author":"J Magae","year":"1996","unstructured":"Magae, J., Wu, C. L., Illenye, S., Harlow, E. & Heintz, N. H. Nuclear localization of DP and E2F transcription factors by heterodimeric partners and retinoblastoma protein family members. J. Cell Sci. 109, 1717\u20131726 (1996).","journal-title":"J. Cell Sci."},{"key":"62295_CR52","first-page":"1325","volume":"58","author":"PL Puri","year":"1998","unstructured":"Puri, P. L. et al. Regulation of E2F4 mitogenic activity during terminal differentiation by its heterodimerization partners for nuclear translocation. Cancer Res. 58, 1325\u20131331 (1998).","journal-title":"Cancer Res."},{"key":"62295_CR53","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/PPO.0b013e31827ab4c4","volume":"18","author":"CB Westphalen","year":"2012","unstructured":"Westphalen, C. B. & Olive, K. P. Genetically Engineered Mouse Models of Pancreatic Cancer. Cancer J. 18, 502\u2013510 (2012).","journal-title":"Cancer J."},{"key":"62295_CR54","doi-asserted-by":"crossref","unstructured":"Yip-Schneider, M. T. et al. Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer 13, 194 (2013).","DOI":"10.1186\/1471-2407-13-194"},{"key":"62295_CR55","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty, G. L. et al. CD40 Agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612\u20131616 (2011).","journal-title":"Science"},{"key":"62295_CR56","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2015.09.022","volume":"28","author":"IM Stromnes","year":"2015","unstructured":"Stromnes, I. M. et al. T Cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell 28, 638\u2013652 (2015).","journal-title":"Cancer Cell"},{"key":"62295_CR57","doi-asserted-by":"crossref","unstructured":"Park, D. et al. Murine models for familial pancreatic cancer:Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains. Plos ONE 14, e0226714 (2019).","DOI":"10.1371\/journal.pone.0226714"},{"key":"62295_CR58","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469\u2013483 (2005).","journal-title":"Cancer Cell"},{"key":"62295_CR59","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nprot.2007.25","volume":"2","author":"CL Morton","year":"2007","unstructured":"Morton, C. L. & Houghton, P. J. Establishment of human tumor xenografts in immunodeficient mice. Nat. Protoc. 2, 247\u2013250 (2007).","journal-title":"Nat. Protoc."},{"key":"62295_CR60","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMra1404198","volume":"371","author":"DP Ryan","year":"2014","unstructured":"Ryan, D. P., Hong, T. S. & Bardeesy, N. Pancreatic adenocarcinoma. N. Engl. J. Med. 371, 2140\u20132141 (2014).","journal-title":"N. Engl. J. Med."},{"key":"62295_CR61","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein, A. P. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat. Rev. Gastroenterol. Hepatol. 18, 493\u2013502 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"62295_CR62","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/gim.2014.153","volume":"17","author":"DB Zhen","year":"2015","unstructured":"Zhen, D. B. et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet. Med. 17, 569\u2013577 (2015).","journal-title":"Genet. Med."},{"key":"62295_CR63","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.tcb.2019.06.005","volume":"29","author":"AK Byrum","year":"2019","unstructured":"Byrum, A. K., Vindigni, A. & Mosammaparast, N. Defining and modulating \u2018BRCAness. Trends Cell Biol. 29, 740\u2013751 (2019).","journal-title":"Trends Cell Biol."},{"key":"62295_CR64","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1086\/318802","volume":"68","author":"MI Ferrante","year":"2001","unstructured":"Ferrante, M. I. et al. Identification of the gene for oral-facial-digital type I syndrome. Am. J. Hum. Genet. 68, 569\u2013576 (2001).","journal-title":"Am. J. Hum. Genet."},{"key":"62295_CR65","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/ejhg.2012.9","volume":"20","author":"M Field","year":"2012","unstructured":"Field, M. et al. Expanding the molecular basis and phenotypic spectrum of X-linked Joubert syndrome associated with OFD1 mutations. Eur. J. Hum. Genet. 20, 806\u2013809 (2012).","journal-title":"Eur. J. Hum. Genet."},{"key":"62295_CR66","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1093\/hmg\/ddq180","volume":"19","author":"A Zullo","year":"2010","unstructured":"Zullo, A. et al. Kidney-specific inactivation of Ofd1 leads to renal cystic disease associated with upregulation of the mTOR pathway. Hum. Mol. Genet. 19, 2792\u20132803 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"62295_CR67","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/ng1684","volume":"38","author":"MI Ferrante","year":"2006","unstructured":"Ferrante, M. I. et al. Oral-facial-digital type I protein is required for primary cilia formation and left-right axis specification. Nat. Genet. 38, 112\u2013117 (2006).","journal-title":"Nat. Genet."},{"key":"62295_CR68","first-page":"19","volume":"26","author":"I Abramowicz","year":"2017","unstructured":"Abramowicz, I. et al. Oral-facial-digital syndrome type I cells exhibit impaired DNA repair; unanticipated consequences of defective OFD1 outside of the cilia network. Hum. Mol. Genet. 26, 19\u201332 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"62295_CR69","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu, Z. I. & O\u2019Reilly, E. M. Therapeutic developments in pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 21, 7\u201324 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"62295_CR70","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","volume":"2","author":"YH Ibrahim","year":"2012","unstructured":"Ibrahim, Y. H. et al. PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2, 1036\u20131047 (2012).","journal-title":"Cancer Discov."},{"key":"62295_CR71","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1158\/0008-5472.CAN-19-2739","volume":"80","author":"ML Luo","year":"2020","unstructured":"Luo, M. L. et al. Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition. Cancer Res. 80, 3033\u20133045 (2020).","journal-title":"Cancer Res."},{"key":"62295_CR72","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","volume":"74","author":"I Bajrami","year":"2014","unstructured":"Bajrami, I. et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity. Cancer Res. 74, 287\u2013297 (2014).","journal-title":"Cancer Res."},{"key":"62295_CR73","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498\u2013503 (2017).","journal-title":"Nature"},{"key":"62295_CR74","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1080\/15548627.2019.1659614","volume":"16","author":"P Li","year":"2020","unstructured":"Li, P. et al. ZNNT1 long noncoding RNA induces autophagy to inhibit tumorigenesis of uveal melanoma by regulating key autophagy gene expression. Autophagy 16, 1186\u20131199 (2020).","journal-title":"Autophagy"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62295-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:58:05Z","timestamp":1757343485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62295-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62295"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62295-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"1 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7209"}}